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ABSTRACT
Studies aiming at improving the treatment of patients 
on insulin therapy are conducted bidirectionally. On 
the one hand, there are attempts to find modified 
insulin that acts even faster and has shorter effect 
than currently used short-acting insulin analogs, and 
on the other hand researchers work to develop more 
stable basal insulins.
Fiasp® is one of the new developments in this field. 
Addition of two excipients — niacinamide and 
L-arginine — resulted in faster hypoglycemic effect of 
insulin aspart while maintaining the stability of drug 
formulation.
Clinical trials assessing pharmacokinetic parameters of 
Fiasp® showed a 2 times faster onset of action (4 vs. 
9 min), 2 times higher exposure to insulin 30 minutes 
after its administration and 74% more hypoglycemic 
activity during the first 30 minutes following subcu-
taneous injection.
Clinical trials of Fiasp® were conducted under the 
acronym Onset. Overall, these studies included over 
3,000 patients with diabetes, both type 1 and type 2. 
In patients with type 1 diabetes (DM1) comparable 
or better diabetes control was observed in the Fiasp® 
groups compared with groups treated with Novorapid, 
with significantly lower blood glucose levels in the 
early postprandial period. It has also been demon-
strated that administration of insulin Fiasp® within 
20 min of  the beginning of the meal was associated 
with comparable results to Novorapid administered 
before the meal.
Fiasp® is commercially available in Poland, but it is not 
yet widely used due to the high price and no reimburse-
ment from NFZ. (Clin Diabetol 2018; 7, 6: 282–286)
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Introduction
Insulin was discovered in 1922 by Banting and Best. 
Commercially available insulin was obtained from pan-
creases of slaughter animals (cows and pigs) and first 
used in 1923. It had different amino acid composition 
than human insulin and contained many xenogeneic-
protein contaminants. Improvement of therapeutic 
insulin consisted in purification of the insulin solution, 
changes in the amino acid sequence, attachment of 
various molecules, and finally modification of the 
primary structure itself, i.e. the change of individual 
amino acids in the native insulin chain. Thanks to the 
use of biotechnology for the production of insulin it 
became possible to obtain preparations practically free 
from other proteins.
Nowadays, patients with diabetes can use many 
insulin preparations that are either human insulin 
equivalents (short-acting human insulin, NPH insulin) 
or its modified forms (insulin analogs). The group 
of currently manufactured insulin analog includes 3 
rapid-acting analogs, aspart, lispro and glulisine, and 
3 analogs providing a sustained, stable release of in-
sulin — glargine, detemir and degludec. There are also 
so-called biosimilar insulins. Thus, there are dozens of 
commercially available insulin preparations that can be 
used in diabetic patients.
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Do we need new insulin preparations, considering 
such a wide range of available therapeutic products? 
What are the expectations of doctors and, above all, 
the needs of patients?
The aim of the currently conducted research is to 
create such insulin preparations that would even better 
mimic physiological concentrations of insulin, both in 
fasting state and after eating a meal, i.e. basic (basal) 
and prandial (bolus) insulin secretion, compared with 
currently available preparations (Figure 1). On the one 
hand, studies are in progress to find insulins with even 
faster and shorter action than known short-acting 
analogs (ultra-rapid insulins), and on the other hand, 
researches are trying to develop longer and more stable 
basal insulins. The expected effect of using such prepa-
rations is to improve the metabolic control in diabetes 
and, at the same time, provide a greater comfort and 
safety of patients.
New fast-acting insulin produced by Novo Nordisk 
under the trade name Fiasp® seems to be a product 
that can meet one of those expectations.
It should be mentioned that two phase 3 clinical 
trials with another new insulin carried out by Lilly have 
been recently completed. Their results will be available 
at the beginning of 2019 [1].
Table 1 summarizes the pharmacological param-
eters of commercially available fast-acting insulin 
analogs.
Pharmacokinetic properties of Fiasp®
Fiasp® (Faster-acting Insulin Aspart) is an Aspart 
insulin formulation that has been enriched with nia-
cinamide (vitamin B3 amide) and amino acid L-arginine. 
Niacinamide was added to increase the absorption of 
insulin after subcutaneous administration, and the 
addition of L-arginine resulted in stabilization of the 
whole molecule [5].
These two excipients are well known; they are 
both included in the American FDA list of inactive 
ingredient that have an neutral effect on the human 
body and, therefore, can be used for the production 
of injectables (Inactive Ingredient Search for Approved 
Drug Products). The concentrations of these substances 
used for the production of Fiasp® are small — lower 
than those used for the production of other drugs. 
These substances are also approved for use during 
pregnancy [6].
In vitro studies in an experimental model using 
vascular endothelial cell lines confirmed that the pres-
ence of niacinamide increases the absorption of insulin 
Aspart monomers by increasing endothelial permeabil-
ity, which is a key mechanism changing the properties 
of insulin Aspart [7].
In 2014–2017 a number of studies were carried 
out aimed at assessing the pharmacokinetic profile, 
pharmacodynamic properties and the safety of Fiasp®. 
These trials resulted in approval of Fiasp® by the FDA 
and EMA.
The results of six single-center, randomized, 
double-blind, cross-over, phase 1 trials that evaluated 
the pharmacological properties of Fiasp® in adult pa-
tients with type 1 diabetes were summarized by Heise 
et al. [8–11]. A total of 218 patients aged 18–64 years 
were randomized to subcutaneous insulin Fiasp® or 
Novorapid at a dose of 0.2 U/kg body weight in order 
to compare the pharmacokinetic parameters of both 
insulins. In some of the participants, metabolic clamp 
studies were performed [5, 12].
Based on the results of the above studies, it was 
found that blood Fiasp® concentration-time curve was 
shifted to the left in relation to blood Novorapid concen-




























Table 1. Selected pharmacological parameters of commercially available insulin analogs









Insulin Aspart/Novorapid/Novo Nordisk [2] 10–20 minutes 60 minutes–3 hours 3–5 hours Immediately before  
or after a meal
Insulin Glulisine/Apidra/Sanofi [3] 10–20 minutes 55 minutes 4–5 hours 0–15 before or after a meal
Insulin Lispro/Humalog and Liprolog/Eli Lilly; 
Insulin Lispro/Sanofi [4]
15 minutes 30–70 minutes 2–5 hours Immediately before  
or after a meal
Figure 1. Profiles of action of different insulins
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insulin delivery to its maximum concentration in the 
blood (tmax) and the time to maximum glucose reduc-
tion (tGIRmax) were shorter for Fiasp
® compared to Novo-
rapid (by 7 and 11 minutes, respectively). Time to 50% 
decrease from maximum concentration (tearly 50% C max) 
was shorter by 10 minutes (decreased by 30%) with 
Fiasp® compared to Novorapid. In addition, the initial 
effect of Fiasp® occurred about 5 minutes earlier (i.e. 
twice as fast compared to Novorapid).
The pooled analysis showed that both the initial 
concentration of insulin in the blood and the early glu-
cose-lowering effect were greater for Fiasp® compared 
to Novorapid within the first 2 hours after injection [12].
During the first 30 minutes after insulin injection, 
a two times higher availability (AUC0–30 min) and a 74% 
higher metabolic effect (AUCGIR, 0–30 min), measured 
by reduction in blood glucose, was found for Fiasp® 
compared with Novorapid [5, 12]. This corresponds to a 
reduction in blood glucose of 51 mg/kg with Fiasp® and 
29 mg/kg with Novorapid (Fiasp®/Novorapid ratio: 1.74 
[95% Cl: 1.47–2.10]) [13]. After reaching the maximum 
concentration (Cmax), the decrease in insulin concentra-
tion was observed earlier for Fiasp® than for Novorapid. 
The difference in time to 50% reduction from the 
maximum blood insulin concentration (tlate 50% C max) 
between Fiasp® and Novorapid was 12.2 min. Similarly, 
the glucose lowering effect occurred earlier for Fiasp® 
compared to Novorapid (the difference in t late 50% GIR max 
was 14.3 minutes) [12].
The maximum glucose-lowering effect occurred 
between 1 and 3 hours after the injection. The total glu-
cose-lowering effect and maximum glucose-lowering 
effect (GIRmax) were comparable between both insulins. 
Fiasp® had a shorter duration of action compared to 
Novorapid insulin and it was 3–5 hours.
In the therapeutic dose range, a linear relationship 
between Fiasp® dose and glucose lowering effect was 
observed [13]. This insulin showed low daily intra-individ-
ual variability in reducing blood glucose for early (AUCGIR, 
0–1h, CV ~26%), total (AUCGIR, 0–12h, CV ~18%), and the 
maximum glucose-lowering effect (GIRmax, CV ~19%) [9, 
13]. There were no differences in the maximum glucose-
lowering effect between patients of different ages [10]. 
Similar results in relation to postprandial glucose were 
also obtained in the Japanese study [14].
Clinical trials — assessment  
of clinical effectiveness
Clinical studies of Fiasp®, referred as the Onset 
trials, were carried out in various populations of pa-
tients with type 1 and type 2 diabetes. In total, these 
trials included over 3,000 patients. Table 2 presents 
the characteristics and main results of the Onset tri-
als in the population of patients with type 1 diabetes 
mellitus (DM1).
The trials in DM1 patients showed comparable or 
better glycemic control in the Fiasp® groups compared 
with Novorapid groups, with significantly lower blood 
glucose levels in the early postprandial period. No 
increase in the number of hypoglycemic episodes was 
observed in the Fiasp® groups, and in the study with 
basal insulin degludec there were less episodes of late 
postprandial hypoglycemia. It is worth noting that ad-
ministration of Fiasp® within 20 min of the beginning 
of the meal was associated with comparable results 
to those obtained with Novorapid given before meals 
Table 2. The results of the Onset trials comparing Fiasp® and Novorapid used for intensive insulin therapy in patients 
with type 1 diabetes
Name of the trial Diabetes  
treatment 




Postprandial blood  
glucose Fiasp® vs. Novorapid
Hypoglycemic  
episodes
Onset 1 [15] Insulin Levemir 1143/52 weeks –0.08 vs. +0.01%  
p < 0.0424
Change in favor of Fiasp®:  
–14.3 vs. +2.5 
p < 0.005
No difference
Onset 8 [16] Basal insulin  
degludec
1025/26 weeks Comparable Confirmed better postprandial 
glycemic control in the  
Fiasp® group p < 0.05
No difference
Onset 4 [17] Insulin  
pump
37/6 weeks Comparable A trend towards lower  
postprandial glucose  
levels in the Fiasp® group 
No difference
Onset 5 [18] Insulin pump  
(with CGM)
472/16 weeks Non-inferior to insulin 
Aspart, but smaller 
HbA1c reduction in  
the Fiasp® group
Confirmed better  
postprandial glycemic  
control in the Fiasp® group  
p < 0.05
No difference
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(Onset 8). The authors of the study conclude that the 
use of Fiasp® enables obtaining a glycemic profile that 
is closer to physiological [19].
Overall, Fiasp® was evaluated in 921 patients with 
type 2 diabetes mellitus (DM2). The Onset 2 trial com-
pared two meal-time insulins, Fiasp® or Novorapid, in 
patients previously treated with metformin and basal 
insulin. There were no significant differences in diabetes 
control (noninferiority trial), although Fiasp® caused 
a greater reduction in blood glucose 60 min after a 
meal compared to Novorapid (38.5 vs. 27.9, p = 0.019), 
no such difference was found within 2–4 hours after 
a meal [20]. The reduction in postprandial blood glucose 
and body weight as well as overall safety profile were 
similar in both groups, but the risk of early-postprandial 
hypoglycemia (0–2 h) was higher in patients using 
Fiasp®. If in patients with poorly controlled diabetes 
(HbA1c 7.0–9.5% at baseline) on metformin and basal 
insulin (Onset 3) Fiasp® was added, while in the control 
group of patients previous treatment was maintained, 
a significantly higher reduction of HbA1c was obtained 
(1.2 vs. 0.2%, p = 0.0001), as expected; however, at the 
cost of a greater number of hypoglycemic events (severe 
and confirmed hypoglycemia: 58.3 vs. 25.0%) [21].
No significant differences in the body weight of 
study participants were found in the studies mentioned 
above. In the Onset 5 trial, there were more skin reac-
tions at the injection site in patients receiving Fiasp® 
by continuous subcutaneous insulin infusion. No other 
significant side effects were found.
Prescription form
Fiasp® is a clear, aqueous solution that can be ad-
ministered subcutaneously and intravenously. Fiasp® is 
available as a 100 U/mL solution for injection in 3-mL 
penfill cartridges.
According to the manufacturer’s recommenda-
tions, Fiasp® is a mealtime insulin that should be 
administered up to 2 minutes before the meal, but it 
can be taken up to 20 minutes after starting a meal. 
It is recommended that Fiasp® should be injected into 
the subcutaneous tissue of the abdomen or arm, which 
results in a faster onset of action [22].
The dosage of Fiasp®, like all other insulins, should 
be adjusted individually and determined in accordance 
with the patient’s needs. The duration of action may 
vary depending on the dose, injection site, blood flow, 
body and ambient temperature, and the level of physi-
cal activity of the patient.
The potency of Fiasp® corresponds to 1 inter-
national unit of human insulin or 1 unit of another 
rapid-acting insulin analog; therefore, there is no 
need to modify the dose when changing from another 
rapid-acting insulin formulation, but obviously it may 
be necessary to adjust the doses and dosing time of 
concomitantly used medium- or long-acting insulins 
or adjustment of other antidiabetic treatment. Fiasp® 
has not been registered in patients < 18 years of age.
Summary
The authors of the studies performed conclude 
that Fiasp® allows for better mimicking of the physi-
ological secretion of insulin compared with Novorapid 
[14, 15, 19]. Pharmacokinetic studies showed a twice 
rapid onset of action (4 vs. 9 min) and 2 times higher 
exposure to insulin at 30 min after its administration 
and 74% more hypoglycemic activity during the first 
30 minutes following subcutaneous injection.
The results of the above-discussed trials including 
various groups of patients suggest that Fiasp® may be a 
good alternative for patients using functional, intensive 
insulin therapy, both multiple subcutaneous injections 
and CSII (insulin pump). Although this has not been 
directly demonstrated in clinical studies, Fiasp® can 
be particularly useful if patients’ diet is rich in simple 
carbohydrates, or if used instead of regular analog for 
selected meals. It would be an alternative therapy for 
patients who are well-educated and actively involved 
in their own management. However, it can be expected 
that the largest group of patients using Fiasp® will be 
patients who are unable to keep, for various reasons 
(e.g., short breaks for meals at work and at school, 
hurry in eating meals, etc.), the time between insulin 
injections and meal intake, and those who are tired 
with constant time control. This group may include 
both very active and independent patients, and those 
dependent on caregivers, e.g. nursing home residents. 
Approval of Fiasp® for use in children can significantly 
improve their quality of life.
Although registered for use in Poland, Fiasp® is 
not yet widely available for patients due to the high 
price and the lack of reimbursement by the NFZ. It 
is expected that this insulin can potentially improve 
metabolic control in patients with diabetes, but only the 
widespread availability of Fiasp® will allow follow-up 
and more accurately defining groups of patients with 
diabetes who will benefit from its use.
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